The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult depression: A meta-analysis

European Psychiatry

Volumn 30, Issue 6, 2015, Pages 685-693

  Cuijpers, P ^a,b   Karyotaki, E ^a,b   Andersson, G ^c,d   Li, J ^e   Mergl, R ^f   Hegerl, U ^f  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e INSTITUTE OF PSYCHOLOGY   (China)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cognitive behavior therapy; Major depression; Meta analysis; Pharmacotherapy; Psychotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT DISEASE; COGNITIVE THERAPY; DEPRESSION; DYSTHYMIA; HUMAN; INTERMETHOD COMPARISON; MAJOR DEPRESSION; META ANALYSIS; PRIORITY JOURNAL; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT OUTCOME; ADULT; DOUBLE BLIND PROCEDURE; PLACEBO EFFECT; PROCEDURES;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; HUMANS; PLACEBO EFFECT; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941022289     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.06.005     Document Type: Short Survey

References (66)

1. Adli M., Hegerl U. Do we underestimate the benefits of antidepressants. Lancet 2014, 383:1361-1362.
2. Barber J., Barrett M.S., Gallop R., Rynn M.A., Rickels K. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2012, 73:66-73.
3. Barrett J.E., Williams J.W., Oxman T.E., Frank E., Katon W., Sullivan M., et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001, 50:405-412.
4. Bedi N., Chilvers C., Churchill R., Dewey M., Duggan C., Fielding K., et al. Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. Br J Psychiatr 2000, 177:312-318.
5. Blackburn I.M., Bishop S., Glen A.I., Whalley L.J., Christie J.E. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981, 139:181-189.
6. Blackburn I.M., Moore R.G. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with current depression. Br J Psychiatry 1997, 171:328-334.
7. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to meta-analysis 2009, Wiley, Chichester, UK.
8. Browne G., Steiner M., Roberts J., Gafni A., Byrne C., Dunn E., et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Dis 2002, 68:317-330.
9. Cohen J. Statistical power analysis for the behavioral sciences 1988, Erlbaum, Hillsdale, NJ. 2nd ed.
10. Cuijpers P., Hollon S.D., van Straten A., Bockting C., Berking M., Andersson G. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy?. A meta-analysis. BMJ Open 2013, 3. 10.1136/bmjopen-2012-002542.
11. Cuijpers P., Sijbrandij M., Koole S.L., Andersson G., Beekman A.T., Reynolds C.F. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 2013, 12:137-148.
12. Cuijpers P., Turner E.H., Koole S.L., van Dijke A., Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depress Anx 2014, 31:374-378.
13. Cuijpers P., van Straten A., van Oppen P., Andersson G. Are psychological and pharmacological interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008, 69:1675-1685.
14. Cuijpers P., van Straten A., Warmerdam L., Andersson G. Psychological treatment of depression: a meta-analytic database of randomized studies. BMC Psychiatry 2008, 8:36.
15. David D., Szentagotai A., Lupu V., Cosman D. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, post-treatment outcomes, and 6-month follow-up. J Clin Psychol 2008, 64:728-746.
16. Dekker J.J.M., Koelen J.A., Van H.L., Schoevers R.A., Peen J., Hendriksen M., et al. Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affective Disord 2008, 109:183-188.
17. Dunlop B.W., Kelley M.E., Mletzko T.C., Velasquez C.M., Craighead W.E., Mayberg H.S. Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res 2012, 46:375-381.
18. Dunner D.L., Schmaling K.B., Hendrickson H., Becker J., Lehman A., Bea C. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depress 1996, 4:34-41.
19. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
20. Elkin I., Shea M.T., Watkins J.T., Imber S.D., Sotsky S.M., Collins J.F., et al. General effectiveness of treatments. Arch Gen Psychiatry 1989, 46:971-982.
21. Finkenzeller W., Zobel I., Rietz S., Schramm E., Berger M. Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness. Nervenarzt 2009, 80:805-812.
22. Fisher S., Greenberg R.P. How sound is the double-blind design for evaluating psychotropic drugs?. J Nerv Ment Dis 1993, 181:345-350.
23. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
24. Frank E., Cassano G.B., Rucci P., Thompson W.K., Kraemer H.C., Fagiolini A., et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011, 41:151-162.
25. Hedges L.V., Olkin I. Statistical methods for meta-analysis 1985, Academic Press, San Diego, CA.
26. Hegerl U., Allgaier A.K., Henkel V., Mergl R. Can effects of antidepressants in patients with mild depression be considered as clinically significant?. J Affect Disord 2012, 138:183-191.
27. Hegerl U., Hautzinger M., Mergl R., Kohnen R., Schütze M., Scheunemann W., et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients? Choice arm. Int J Neuropsychopharmacol 2010, 13:31-44.
28. Hegerl U., Mergl R. The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 2010, 24:445-448.
29. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011, http://www.cochrane-handbook.org/.
30. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
31. Hollon S.D., DeRubeis R.J., Evans M.D., Wiemer M.J., Garvey M.J., Grove W.M., et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry 1992, 49:774-781.
32. Ioannidis J.P.A., Patsopoulos N.A., Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914-916.
33. Jarrett R.B., Schaffer M., McIntire D., Witt-Browder A., Kraft D., Risser R.C. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999, 56:431-437.
34. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000, 342:1462-1470.
35. Kirsch I. Benefits of antidepressants over placebo limited except in very severe depression. Evid Based Ment Health 2010, 13:49.
36. Kraemer H.C., Kupfer D.J. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006, 59:990-996.
37. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. New Engl J Med 1988, 318:1728-1733.
38. Lesperance F., Frasure-Smith N., Koszycki D., Lalibert M.A., van Zyl L.T., Baker B., et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 2007, 297:367-379.
39. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6(7):e1000100. 10.1371/journal.pmed.1000100.
40. Markowitz J.C., Kocsis J.H., Bleiberg K.L., Christos P.J., Sacks M. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Dis 2005, 89:167-175.
41. Marshall M.B., Zuroff D.C., McBride C., Bagby R.M. Self-criticism predicts differential response to treatment for major depression. J Clin Psychol 2008, 64:231-244.
42. Martin S.D., Martin E., Rai S.S., Richardson M.A., Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001, 58:641-648.
43. McBride C., Segal Z., Kennedy S., Gemar M. Changes in autobiographical memory specificity following cognitive behavior therapy and pharmacotherapy for major depression. Psychopathol 2007, 40:147-152.
44. McHugh R.K., Whitton S.W., Peckham A.D., Welge J.A., Otto M.W. Patient preference for psychological vs pharmacological treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry 2013, 74:595-602.
45. McKnight D.L., Nelson-Gray R.O., Barnhill J. Dexamethasone suppression test and response to cognitive therapy and antidepressant medication. Behav Ther 1992, 23:99-111.
46. Mohr D.C., Boudewyn A.C., Goodkin D.E., Bostrom A., Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001, 69:942-949.
47. Mohr D.C., Ho J., Hart S.L., Baron K.G., Berendsen M., Beckner V., et al. Control condition design and implementation features in controlled trials: a meta-analysis of trials evaluating psychotherapy for depression. Transl Behav Med 2014, [epub ahead of print].
48. Mohr D.C., Spring B., Freedland K.E., Beckner V., Arean P., Hollon S.D., et al. The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009, 78:275-284.
49. Moncrieff J., Wessely S., Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004, 1:CD003012.
50. Moradveisi L., Huibers M.J.H., Renner F., Arasteh M., Arntz A. Behavioural activation v. antidepressant medication for treating depression in Iran: randomised trial. Br J Psychiatry 2013, 202:204-211.
51. Murphy G.E., Simons A.D., Wetzel R.D., Lustman P.J. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry 1984, 41:33-41.
52. Mynors-Wallis L.M., Gath D.H., Day A., Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000, 320:26-30.
53. Mynors-Wallis L.M., Gath D.H., Lloyd-Thomas A.R., Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995, 310:441-445.
54. Nutt D.J., Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacology 2008, 22:3-6.
55. Orsini N., Higgins J., Bottai M., Buchan I. Heterogi: Stata module to quantify heterogeneity in a meta-analysis 2005, [accessed 27 February 2013]. http://econpapers.repec.org/RePEc:boc:bocode:s449201.
56. Ravindran A.V., Anisman H., Merali Z., Charbonneau Y., Telner J., Bialik R.J., et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 1999, 156:1608-1617.
57. Reynolds C.F., Miller M.D., Pasternak R.E., Frank E., Perel J.M., Cornes C., et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999, 156:202-208.
58. Rush A.J., Beck A.T., Hollon S.D., et al. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cogn Ther Res 1977, 1:17-37.
59. Rutherford B.R., Roose S.P. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013, 170:723-733.
60. Salminen J.K., Karlsson H., Hietala J., Kajander J., Aalto S., Markkula J., et al. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom 2008, 77:351-357.
61. Shamsaei F., Rahimi A., Zarabian M.K., Sedehi M. Efficacy of pharmacotherapy and cognitive therapy, alone and in combination in major depressive disorder. Hong Kong J Psychiatry 2008, 18:76-80.
62. Sharp D.J., Chew-Graham C., Tylee A., Lewis G., Howard L., Anderson I., et al. A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. Health Technol Assess 2010, 14:43.
63. Sinyor M., Levitt A.J., Cheung A.H., Schaffer A., Kiss A., Dowlati Y., et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010, 71:270-279.
64. Sneed J.R., Rutherford B.R., Rindskopf D., Lane D.T., Sackeim H.A., Roose S.P. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriat Psychiatry 2008, 16:65-73.
65. Thompson L.W., Coon D.W., Gallagher-Thompson D., Sommer B.R., Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry 2001, 9:225-240.
66. Williams J.W., Barrett J., Oxman T., Frank E., Katon W., Sullivan M., et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000, 284:1519-1526.